PEN

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

High

288.620

Open

286.150

VWAP

274.09

Vol

1.43M

Mkt Cap

10.66B

Low

265.0001

Amount

391.89M

EV/EBITDA(TTM)

62.27

Total Shares

38.76M

10.84B

EV/OCF(TTM)

60.48

P/S(TTM)

9.21

Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

327.28M

+9.31%

0.830

+29.72%

342.06M

+13.63%

0.971

+14.28%

361.11M

+14.45%

1.140

+17.57%

Estimates Revision

The market is revising Downward the revenue expectations for Penumbra, Inc. (PEN) for FY2025, with the revenue forecasts being adjusted by -0.4% over the past three months. During the same period, the stock price has changed by 1.54%.

Revenue Estimates for FY2025

Revise Downward

-0.4%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.06%

In Past 3 Month

Stock Price

Go Up

+1.54%

In Past 3 Month

16 Analyst Rating

14.78% Upside

Wall Street analysts forecast PEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEN is 316.00 USD with a low forecast of 260.00 USD and a high forecast of 340.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

3 Hold

0 Sell

Strong Buy

14.78% Upside

Current: 275.320

Low

260.00

Averages

316.00

High

340.00

14.78% Upside

Current: 275.320

Low

260.00

Averages

316.00

High

340.00

Wells Fargo

Larry Biegelsen

Buy

Maintains

$305 → $315

2025-04-24

Reason

Wells Fargo

Larry Biegelsen

Price Target

$305 → $315

2025-04-24

Maintains

Buy

Reason

Stifel

Mathew Blackman

Strong Buy

Maintains

$301 → $318

2025-04-24

Reason

Stifel

Mathew Blackman

Price Target

$301 → $318

2025-04-24

Maintains

Strong Buy

Reason

Stifel analyst Mathew Blackman raised the firm's price target on Penumbra to $318 from $301 and keeps a Buy rating on the shares. Q1 results were "across-the-board ahead of expectations" and the company re-affirmed or raised key guidance metrics, says the analyst, who sees Penumbra "emerging as a port in stormy waters."

Truist Securities

David Rescott

Strong Buy

Maintains

$315 → $330

2025-04-24

Reason

Truist Securities

David Rescott

Price Target

$315 → $330

2025-04-24

Maintains

Strong Buy

Reason

Truist raised the firm's price target on Penumbra to $330 from $315 and keeps a Buy rating on the shares. The company's Q1 revenue outperformance was led by another strong U.S. Thrombectomy performance, while its margin control helped power a solid EPS beat, the analyst tells investors in a research note.

UBS

Priya Sachdeva

Strong Buy

Maintains

$320 → $330

2025-04-24

Reason

UBS

Priya Sachdeva

Price Target

$320 → $330

2025-04-24

Maintains

Strong Buy

Reason

UBS raised the firm's price target on Penumbra to $330 from $320 and keeps a Buy rating on the shares. Relatively limited macro exposure leaves room for potential upside, the analyst tells investors in a research note.

RBC Capital

Shagun Singh

Buy

Maintains

$315 → $330

2025-04-24

Reason

RBC Capital

Shagun Singh

Price Target

$315 → $330

2025-04-24

Maintains

Buy

Reason

RBC Capital raised the firm's price target on Penumbra to $330 from $315 and keeps an Outperform rating on the shares. The company delivered a Q1 beat, and maintained 2025 guidance despite China headwinds and given its recent guidance philosophy of conservatism, the analyst tells investors in a research note. Penumbra's business momentum is robust as it posted solid high-teens underlying growth in Q1 ex-China, the firm adds.

Truist Securities

David Rescott

Strong Buy

Maintains

$325 → $315

2025-04-11

Reason

Truist Securities

David Rescott

Price Target

$325 → $315

2025-04-11

Maintains

Strong Buy

Reason

Truist analyst Richard Newitter lowered the firm's price target on Penumbra to $315 from $325 and keeps a Buy rating on the shares as part of a broad research note previewing Q1 results in Medical Technology. The group's revenue and earnings are less at risk than it could be for a number of other sub-sectors, which will likely keep investors relatively interested in the space even with some tariff choppiness in the backdrop, though the firm is also bracing for cautious 2025 outlooks as companies and models will likely begin to dial-in some macro uncertainty, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Penumbra Inc (PEN.N) is 72.09, compared to its 5-year average forward P/E of 267.31. For a more detailed relative valuation and DCF analysis to assess Penumbra Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

267.31

Current PE

72.09

Overvalued PE

545.24

Undervalued PE

-10.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

110.40

Current EV/EBITDA

46.35

Overvalued EV/EBITDA

174.27

Undervalued EV/EBITDA

46.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

9.35

Current PS

8.19

Overvalued PS

12.05

Undervalued PS

6.65